Recursion's AI-designed cancer drugs REC-3565 and REC-617 show early clinical promise, with one patient responding ...

Earlier this week, a prominent venture capitalist named Geoff Lewis — the managing partner of the multi-billion dollar investment firm Bedrock, which has backed high-profile tech companies including ...

IGIS Tech Notes describe workflows and techniques or using geospatial science and technologies in research and extension. They are works in progress, and we welcome feedback and comments below. 360 ...

RXRX gains 5.5% in a month on positive pipeline update; long-term hold advised given strong potential of its AI-driven drug discovery platform.

Recursion Pharmaceuticals stock jumps after securing full rights to REV102, aiming to fast-track the first oral therapy for hypophosphatasia.

While AI-driven approaches tout increased speed and lower costs, commercial interests compromise scientific collaboration.

Former Google CEO Eric Schmidt warns that Artificial Superintelligence (ASI), surpassing human intelligence, is imminent. He ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.27, marking a +1.15% move from the previous day. The stock's performance was ahead of the S&P 500's daily gain of 0.83%. At ...